LSE:BPCR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BioPharma Credit PLC, a specialist life sciences debt investment trust, primarily invests in interest-bearing debt assets. More Details


Snowflake Analysis

Flawless balance sheet and fair value.

Share Price & News

How has BioPharma Credit's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BPCR is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 1% a week.

Volatility Over Time: BPCR's weekly volatility (1%) has been stable over the past year.


Market Performance


7 Day Return

-0.4%

BPCR

-5.6%

GB Capital Markets

1.2%

GB Market


1 Year Return

-1.4%

BPCR

11.2%

GB Capital Markets

4.6%

GB Market

Return vs Industry: BPCR underperformed the UK Capital Markets industry which returned 11.2% over the past year.

Return vs Market: BPCR underperformed the UK Market which returned 4.6% over the past year.


Shareholder returns

BPCRIndustryMarket
7 Day-0.4%-5.6%1.2%
30 Day-2.0%-6.6%0.9%
90 Day-0.1%0.06%2.4%
1 Year4.0%-1.4%14.8%11.2%10.6%4.6%
3 Year16.2%-5.2%39.5%23.7%8.6%-4.5%
5 Yearn/a99.0%65.5%39.5%12.5%

Long-Term Price Volatility Vs. Market

How volatile is BioPharma Credit's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioPharma Credit undervalued compared to its fair value and its price relative to the market?

16.2x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BPCR ($0.98) is trading above our estimate of fair value ($0.86)

Significantly Below Fair Value: BPCR is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BPCR is good value based on its PE Ratio (16.2x) compared to the GB Capital Markets industry average (20.1x).

PE vs Market: BPCR is good value based on its PE Ratio (16.2x) compared to the UK market (24.1x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BPCR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BPCR is good value based on its PB Ratio (1x) compared to the GB Capital Markets industry average (1.6x).


Next Steps

Future Growth

How is BioPharma Credit forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.8%

Forecasted Diversified Financials industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioPharma Credit has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BioPharma Credit performed over the past 5 years?

-28.0%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: BPCR has high quality earnings.

Growing Profit Margin: BPCR's current net profit margins (73.6%) are lower than last year (80.9%).


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if BPCR's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: BPCR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BPCR had negative earnings growth (-28%) over the past year, making it difficult to compare to the Capital Markets industry average (-1.9%).


Return on Equity

High ROE: BPCR's Return on Equity (6%) is considered low.


Next Steps

Financial Health

How is BioPharma Credit's financial position?


Financial Position Analysis

Short Term Liabilities: BPCR's short term assets ($64.3M) exceed its short term liabilities ($31.4M).

Long Term Liabilities: BPCR's short term assets ($64.3M) exceed its long term liabilities ($564.0K).


Debt to Equity History and Analysis

Debt Level: BPCR is debt free.

Reducing Debt: BPCR has not had any debt for past 5 years.

Debt Coverage: BPCR has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: BPCR has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is BioPharma Credit current dividend yield, its reliability and sustainability?

8.48%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: BPCR's dividend (8.48%) is higher than the bottom 25% of dividend payers in the UK market (1.49%).

High Dividend: BPCR's dividend (8.48%) is in the top 25% of dividend payers in the UK market (4.51%)


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, BPCR has been paying a dividend for less than 10 years.

Growing Dividend: BPCR's dividend payments have increased, but the company has only paid a dividend for 3 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (116.2%), BPCR's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average board tenure


CEO

BioPharma Credit has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Rolf Kristian Berndtson Soderstrom
Non-Executive Director0.50yrno data0.0073%
$ 97.6k
Harry Hyman
Independent Chairman0.50yrUS$72.84k0.0075%
$ 100.0k
Duncan Budge
Independent Director4.42yrsUS$70.00k0.0073%
$ 97.6k
Colin Bond
Independent Director4.33yrsUS$85.00k0.0073%
$ 97.6k
Stephanie Léouzon
Independent Non-Executive Director2.25yrsUS$79.78kno data

2.3yrs

Average Tenure

62yo

Average Age

Experienced Board: BPCR's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BioPharma Credit PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioPharma Credit PLC
  • Ticker: BPCR
  • Exchange: LSE
  • Founded: 2016
  • Industry: Asset Management and Custody Banks
  • Sector: Diversified Financials
  • Market Cap: US$1.341b
  • Shares outstanding: 1.37b
  • Website: https://www.bpcruk.com

Location

  • BioPharma Credit PLC
  • Beaufort House
  • 51 New North Road
  • Exeter
  • Devon
  • EX4 4EP
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BPCRLSE (London Stock Exchange)YesOrdinary SharesGBUSDMar 2017
B3PMUN (Boerse Muenchen)YesOrdinary SharesDEEURMar 2017
BPCRLBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBUSDMar 2017
BOPC.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMar 2017

Biography

BioPharma Credit PLC, a specialist life sciences debt investment trust, primarily invests in interest-bearing debt assets. Its assets are secured by royalties or other cash flows derived from the sales of ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/03/06 20:05
End of Day Share Price2021/03/05 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.